葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段抢占RSV疫苗先机

智通财经网06-08

智通财经APP获悉，葛兰素史克公司(GSK.US)在呼吸道合胞病毒(RSV)疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局(FDA)批准，用于50至59岁感染风险较高的成年人群体。这一批准使葛兰素史克成为首家在较年轻人群中获得此类疫苗批准的制药商，为其在秋季RSV高发季节前赢得了市场先机。与辉瑞(PFE.US)和Moderna(MRNA.US)的疫苗相比，葛兰素史克的疫苗现在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2441902511?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-08 14:06","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2441902511","market":"us","top_or_hot":-1,"title":"葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段 抢占RSV疫苗先机","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，葛兰素史克公司(GSK.US)在呼吸道合胞病毒(RSV)疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局(FDA)批准，用于50至59岁感染风险较高的成年人群体。这一批准使葛兰素史克成为首家在较年轻人群中获得此类疫苗批准的制药商，为其在秋季RSV高发季节前赢得了市场先机。与辉瑞(PFE.US)和Moderna(MRNA.US)的疫苗相比，葛兰素史克的疫苗现在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1133112.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段 抢占RSV疫苗先机</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段 抢占RSV疫苗先机\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-08 14:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1133112.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，葛兰素史克公司(GSK.US)在呼吸道合胞病毒(RSV)疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局(FDA)批准，用于50至59岁感染风险较高的成年人群体。这一批准使葛兰素史克成为首家在较年轻人群中获得此类疫苗批准的制药商，为其在秋季RSV高发季节前赢得了市场先机。与辉瑞(PFE.US)和Moderna(MRNA.US)的疫苗相比，葛兰素史克的疫苗现在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1133112.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛欧洲核心股票组合Acc","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1133112.html","article_id":"2441902511","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441902511","pubTimestamp":1717826807,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，葛兰素史克公司在呼吸道合胞病毒疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局批准，用于50至59岁感染风险较高的成年人群体。这一批准使葛兰素史克成为首家在较年轻人群中获得此类疫苗批准的制药商，为其在秋季RSV高发季节前赢得了市场先机。据估计，超过1300万50至59岁的美国人存在感染RSV后产生严重后果的健康风险，这为葛兰素史克提供了巨大的潜在市场。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4007":"制药","GSK":"葛兰素史克","GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓"},"translate_title":"GlaxoSmithKline (GSK.US) Arexvy approved to expand to the age group of 50 to 59 to seize the opportunity of RSV vaccine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"GSK":1,"GSK.UK":0.6},"content_text":"智通财经APP获悉，葛兰素史克公司(GSK.US)在呼吸道合胞病毒(RSV)疫苗领域取得重大进展，其Arexvy疫苗获得美国食品药品监督管理局(FDA)批准，用于50至59岁感染风险较高的成年人群体。这一批准使葛兰素史克成为首家在较年轻人群中获得此类疫苗批准的制药商，为其在秋季RSV高发季节前赢得了市场先机。与辉瑞(PFE.US)和Moderna(MRNA.US)的疫苗相比，葛兰素史克的疫苗现在不仅适用于60岁及以上的成年人，还扩展到了更年轻的年龄段，这可能为其带来更广阔的市场覆盖。值得注意的是，辉瑞的疫苗还可用于孕妇，为她们的新生儿提供保护。RSV是一种严重的病毒，尤其对婴儿和老年人构成威胁，在美国每年导致数万人住院。据估计，超过1300万50至59岁的美国人存在感染RSV后产生严重后果的健康风险，这为葛兰素史克提供了巨大的潜在市场。葛兰素史克在RSV疫苗市场的领先地位得益于Arexvy疫苗的成功推出，该疫苗在上市第一年就实现了超过10亿英镑(约合13亿美元)的销售额，成为公司的重磅产品。这一成就在很大程度上归功于公司首席执行官Emma Walmsley的领导，她成功地将葛兰素史克带向了新的增长轨迹。尽管取得了初步成功，葛兰素史克在即将到来的呼吸道病毒季节仍将面临激烈的市场竞争。Moderna的疫苗，以其预装注射器的便利性，可能会成为有力的竞争者。然而，据彭博情报的分析，Moderna疫苗的有效性下降了 5%，这可能为葛兰素史克提供了进一步巩固市场地位的机会。总体来看，葛兰素史克在RSV疫苗领域的成就不仅展示了其研发实力，也为公司在全球疫苗市场中的竞争力增添了重要一笔。随着秋季RSV季节的临近，葛兰素史克及其竞争对手的表现将受到市场关注。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441902511"}

葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段 抢占RSV疫苗先机

精彩评论

葛兰素史克(GSK.US)Arexvy获批拓宽至50至59岁年龄段抢占RSV疫苗先机